L. Mathieu

Age and sex differences in the incidence of esophageal adenocarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).

M. Brock, C. Rudin, N. Kanarek, 2014, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma

D. Gladstone, N. Ghosh, Y. Kasamon, 2014, Annals of Hematology.

FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

K. Goldberg, R. Pazdur, M. Theoret, 2021, The oncologist.

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers Harboring BRAF V600E Mutations

Reena Philip, K. Goldberg, P. Keegan, 2018, The oncologist.

FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as single agents for first-line treatment of advanced/metastatic PD-L1 high NSCLC.

Jiang Liu, Martha Donoghue, R. Pazdur, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation

Reena Philip, Martha Donoghue, K. Goldberg, 2017, The oncologist.

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations

Jiang Liu, Reena Philip, K. Goldberg, 2021, Clinical Cancer Research.

Survival after community diagnosis of early-stage non-small cell lung cancer.

Hua-Ling Tsai, J. Herman, M. Brock, 2014, The American journal of medicine.

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Martha Donoghue, R. Pazdur, Shenghui Tang, 2022, Journal of Clinical Oncology.

FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI).

R. Pazdur, G. Blumenthal, R. Sridhara, 2019, Journal of Clinical Oncology.